1-17. (canceled)
18. A pharmaceutical composition comprising:
Lyxumia (lixisenatide), Lemtrada (alemtuzumab), REGN727SAR236553 (alirocumab), SAR2405550BSI-201 (iniparib), Otamixaban (otamixaban), Sarilumab (sarilumab), Lantus and Lyxumia (insulin glargine and lixisenatide) or VisamerinMulsevo (semuloparin sodium) and a pharmaceutically acceptable excipient;
wherein the pharmaceutical composition is contained within a glass pharmaceutical container comprising a glass composition comprising:
SiO2 in a an amount greater than or equal to about 72 mol. % and less than or equal to about 78 mol. %;
alkaline earth oxide comprising both MgO and CaO, wherein CaO is present in an amount up to about 1.0 mol. %, and a ratio (CaO (mol. %)(CaO (mol. %)+MgO (mol. %))) is less than or equal to 0.5;
X mol. % Al2O3, wherein X is greater than or equal to about 5 mol. % and less than or equal to about 7 mol. %;
Y mol. % alkali oxide, wherein the alkali oxide comprises Na2O in an amount greater than about 8 mol. %; and
a ratio of a concentration of B7O3 (mol. %) in the glass container to (Y mol. %\u2212X mol. %) is less than or equal to 0.3.
19. The pharmaceutical composition of claim 18, wherein the pharmaceutical container comprises a compressive stress greater than or equal to 150 MPa.
20. The pharmaceutical composition of claim 18, wherein the pharmaceutical container comprises a compressive stress greater than or equal to 250 MPa.
21. The pharmaceutical composition of claim 18, wherein the pharmaceutical container comprises a depth of layer greater than 30 \u03bcm.
22. (canceled)
23. The pharmaceutical composition of claim 18, wherein the pharmaceutical composition comprises increased stability, product integrity, or efficacy.
24. A pharmaceutical composition comprising:
Lyxumia (lixisenatide), Lemtrada (alemtuzumab), REGN727SAR236553 (alirocumab), SAR2405550BSI-201 (iniparib), Otamixaban (otamixaban), Sarilumab (sarilumab), Lantus and Lyxumia (insulin glargine and lixisenatide) or VisamerinMulsevo (semuloparin sodium) and a pharmaceutically acceptable excipient;
wherein the pharmaceutical composition is contained within a glass pharmaceutical container comprising an internal homogeneous layer and a compressive stress greater than or equal to 150 MPa.
25. The pharmaceutical composition of claim 24, wherein the pharmaceutical container comprises a depth of layer greater than 10 \u03bcm.
26. The pharmaceutical composition of claim 25, wherein the pharmaceutical container comprises a depth of layer greater than 25 \u03bcm.
27. The pharmaceutical composition of claim 24, wherein the pharmaceutical container has a delamination factor of less than 3.
28. (canceled)
29. The pharmaceutical composition of claim 24, wherein the pharmaceutical container comprises increased stability, product integrity, or efficacy.
30. A pharmaceutical composition comprising:
Lyxumia (lixisenatide), Lemtrada (alemtuzumab), REGN727SAR236553 (alirocumab), SAR2405550BSI-201 (iniparib), Otamixaban (otamixaban), Sarilumab (sarilumab), Lantus and Lyxumia (insulin glargine and lixisenatide) or VisamerinMulsevo (semuloparin sodium) and a pharmaceutically acceptable excipient;
wherein the pharmaceutical composition is contained within a glass pharmaceutical container having a compressive stress greater than or equal to 150 MPa and a depth of layer greater than 10 \u03bcm, and wherein the pharmaceutical composition comprises increased stability, product integrity, or efficacy.
31. (canceled)
32. A pharmaceutical composition comprising:
Lyxumia (lixisenatide), Lemtrada (alemtuzumab), REGN727SAR236553 (alirocumab), SAR2405550BSI-201 (iniparib), Otamixaban (otamixaban), Sarilumab (sarilumab), Lantus and Lyxumia (insulin glargine and lixisenatide) or VisamerinMulsevo (semuloparin sodium) and a pharmaceutically acceptable excipient;
wherein the pharmaceutical composition is contained within a glass pharmaceutical container comprising a delamination factor of less than 3, wherein the pharmaceutical composition comprises increased stability, product integrity, or efficacy.
33. A pharmaceutical composition comprising:
Lyxumia (lixisenatide), Lemtrada (alemtuzumab), REGN727SAR236553 (alirocumab), SAR2405550BSI-201 (iniparib), Otamixaban (otamixaban), Sarilumab (sarilumab), Lantus and Lyxumia (insulin glargine and lixisenatide) or VisamerinMulsevo (semuloparin sodium) and a pharmaceutically acceptable excipient;
wherein the pharmaceutical composition is contained within a glass pharmaceutical container which is substantially free of boron, and wherein the pharmaceutical composition comprises increased stability, product integrity, or efficacy.
34. The pharmaceutical composition of claim 33, wherein the glass pharmaceutical container comprises a compressive stress greater than or equal to 150 MPa and a depth of layer greater than 25 \u03bcm.
35. The pharmaceutical composition of claim 34, wherein the glass pharmaceutical container comprises a compressive stress greater than or equal to 300 MPa and a depth of layer greater than 35 \u03bcm.
36. The pharmaceutical composition of claim 33, wherein said glass pharmaceutical container comprises a substantially homogeneous inner layer.
37. The pharmaceutical composition of claim 36, wherein said glass pharmaceutical container comprises a compressive stress greater than or equal to 150 MPa and a depth of layer greater than 25 \u03bcm.
38-44. (canceled)
45. The pharmaceutical composition of claim 18, wherein the pharmaceutical container comprises an internal homogeneous layer.
46. The pharmaceutical composition of claim 27, wherein the pharmaceutical container comprises increased stability, product integrity, or efficacy.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A mounting assembly for a wheel suspension system of a vehicle having a vehicle body, said mounting assembly comprising:
a support structure having an aperture and adapted to be mounted to the vehicle body;
a piston rod at least partially disposed within said aperture and displaceable relative to said support structure along a line of travel;
a plate mounted to said piston rod and moving relative to said support structure during said displacement of said piston rod;
an insulator disposed about said piston rod between said support structure and said plate with said insulator abutting said plate for coupling said piston rod to said support structure;
said insulator having a first portion defining a first resistance and a first maximum width for isolating said displacement of said piston rod and said plate during an application of a first force along said line of travel in a first direction which at least partially compresses said first portion, and a second portion defining a second resistance and a second maximum width with said second resistance being greater than said first resistance for controlling said displacement of said piston rod and said plate after said application of said first force and during an application of a second force along said line of travel in said first direction wherein said second force is greater than said first force such that both said first and second portions are at least partially compressed and said second width being larger than said first width to define a ledge on said second portion extending outwardly beyond said width of said first portion; and
a jounce bumper disposed about said piston rod and mounted to said plate on an opposite side from said insulator for translating movement of the wheel suspension system during application of said second force;
said plate having a width at least equal to said maximum width of said second portion and a maximum width of said jounce bumper;
said support structure including a first cup defining a cavity and an inner surface with said first portion of said insulator at least partially disposed within said cavity and configured to be contiguous with said inner surface for compressing said first portion without compressing said ledge and said second portion when said first force is applied;
said support structure further including a flange extending outwardly from said first cup with said flange uniformly positioned relative to said ledge for positioning said ledge between said flange and said plate such that during said application of said second force, said ledge of said second portion engages and compresses against said flange to transmit loads of said second force from said plate to said support structure.
2. The assembly as set forth in claim 1 wherein said first portion is at least partially compressed before said second portion is at least partially compressed.
3. The assembly as set forth in claim 1 wherein said first and second portions of said insulator are formed of a common homogeneous material of micro-cellular polyurethane.
4. The assembly as set forth in claim 1 wherein said first portion has a first height and said second portion has a second height smaller than said first height.
5. The assembly as set forth in claim 1 wherein said piston rod includes a notch with said plate abutting said notch to mount said plate to said piston rod.
6. The assembly as set forth in claim 1 wherein said first and second portions of said insulator are formed of the same material.
7. The assembly as set forth in claim 4 wherein said first height is 3 times larger than said second height.
8. The assembly as set forth in claim 1 wherein said first portion has an annular configuration defining a first circumference.
9. The assembly as set forth in claim 8 wherein said second portion has an annular configuration defining a second circumference which is larger than said first circumference to define an annular ledge on said second portion extending outwardly beyond said circumference of said first portion.
10. The assembly as set forth in claim 9 wherein said first portion and said second portion having said annular ledge are formed of a common homogeneous material.
11. The assembly as set forth in claim 1 wherein said insulator is mounted to said piston rod.
12. The assembly as set forth in claim 1 further including a second insulator mounted to said support structure for further coupling said piston rod to said support structure and for further isolating said displacement of said piston rod and said plate when said first force is applied along said line of travel in said first direction.
13. The assembly as set forth in claim 12 wherein said support structure includes a second cup with said second insulator mounted within said second cup.